Resmed Stock News

WASHINGTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Ventilator Market finds that the outbreak of the covid-19 pandemic, increasing geriatric population, growing number of preterm births, large emergence of respiratory diseases and increasing requirement for ICU beds are expected to witness the maximum growth of Ventilator market during the projected years. The total Global Ventilator Market is estimated to reach USD 9.09 Billion by 2028, up from USD 6.59 Billion in 2021, at a compound annual growth rate (CAGR) of 7.1%, states Vantage Market Research, in a report, titled " Ventilator Market by Mobility (Intensive Care Ventilators, Portable Ventilators), by Interface (Invasive Ventilation, Non-Invasive Ventilation), by End-User (Hospitals, Home Healthcare, Other End Users), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)". Please Check Out Our Free Sample Reports and Make a More Informed Decision: Get Access to a Free Copy of Our Latest Sample Report @ https://www.vantagemarketresearch.com/ventilator-market-1282/request-sample (Sample reports are a great way to test our in-depth reports or study before you make a purchase) The newly updated, 150+ page reports provide an in-depth analysis of the COVID-19 virus and pandemic.

ResMed Inc. found using ticker (RMD) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 312 and 235 calculating the mean target price we have 268. With the stocks previous close at 234.24 this is indicating there is a potential upside of 14.4%. There is a 50 day moving average of 245.2 while the 200 day moving average is 252.14. The market cap for the company is $33,887m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets=RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $38,771m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Citi Healthcare Conference on Wednesday, February 23, 2022, beginning at approximately 12:30 p.m. (Eastern Standard Time) via webcast.

ResMed Inc. with ticker code (RMD) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 312 and 235 and has a mean target at 268. With the stocks previous close at 244.35 this is indicating there is a potential upside of 9.7%. The day 50 moving average is 247.85 and the 200 day MA is 251.08. The company has a market capitalisation of $35,669m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" symbol="RMD" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $39,122m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

ResMed (RMD) has appointed Urvashi Tyagi to the role of Chief Technology Officer ((CTO)).Tyagi will head the company''s digital health technology team, driving innovation of its…

RBC Capital Markets has upgraded ResMed from under perform to market perform even though the company''s fiscal Q2 2022 results missed on the top and bottom lines.

ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.

ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations as the business faced increas

RMD earnings call for the period ending December 31, 2021.

ResMed Inc. (RMD) CEO Mick Farrell on Q2 2022 Results - Earnings Call Transcript

ResMed press release (RMD): FQ2 Non-GAAP EPS of $1.47 misses by $0.05.Revenue of $894.9M (+11.9% Y/Y) misses by $32.59M.Gross margin of 56.4%; non-GAAP gross margin contracted 230…